Technical Analysis for ZYNE - Zynerba Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 5.78 -6.02% -0.37
ZYNE closed down 6.02 percent on Friday, March 22, 2019, on 80 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ZYNE trend table...

Date Alert Name Type % Chg
Mar 22 New Uptrend Bullish 0.00%
Mar 22 Upper Bollinger Band Walk Strength 0.00%
Mar 22 Inside Day Range Contraction 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 22 Upper Bollinger Band Touch Strength 0.00%
Mar 21 Calm After Storm Range Contraction -6.02%
Mar 21 Wide Range Bar Range Expansion -6.02%
Mar 21 Stochastic Reached Overbought Strength -6.02%
Mar 21 Upper Bollinger Band Walk Strength -6.02%

Older signals for ZYNE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company has two product candidates, including ZYN002 and ZYN001, which represent cannabinoid therapeutics for several indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. ZYN002 is a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In preclinical animal studies, ZYN002's permeation enhancer increased delivery of CBD through the layers of the skin and into the circulatory system. ZYN001 is a pro-drug of delta-9-tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. In preclinical animal studies, ZYN001 demonstrated effective skin permeation with sustained delivery and rapid conversion of ZYN001 to THC.
Pharmaceutical Pain Drugs Chemical Compounds Osteoarthritis Psychoactive Drugs Entheogens Cannabinoids Fibromyalgia Fragile X Syndrome Transdermal
Is ZYNE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.5
52 Week Low 2.75
Average Volume 1,176,280
200-Day Moving Average 6.4829
50-Day Moving Average 4.9042
20-Day Moving Average 5.178
10-Day Moving Average 5.35
Average True Range 0.4426
ADX 25.19
+DI 32.6308
-DI 14.4508
Chandelier Exit (Long, 3 ATRs ) 5.0722
Chandelier Exit (Short, 3 ATRs ) 5.7928
Upper Bollinger Band 6.0282
Lower Bollinger Band 4.3278
Percent B (%b) 0.85
BandWidth 32.838934
MACD Line 0.2244
MACD Signal Line 0.1194
MACD Histogram 0.105
Fundamentals Value
Market Cap 76.63 Million
Num Shares 13.3 Million
EPS -2.60
Price-to-Earnings (P/E) Ratio -2.22
Price-to-Sales 0.00
Price-to-Book 1.77
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.50
Resistance 3 (R3) 6.54 6.34 6.38
Resistance 2 (R2) 6.34 6.16 6.32 6.34
Resistance 1 (R1) 6.06 6.04 5.96 6.02 6.30
Pivot Point 5.86 5.86 5.81 5.84 5.86
Support 1 (S1) 5.58 5.68 5.48 5.54 5.26
Support 2 (S2) 5.38 5.56 5.36 5.22
Support 3 (S3) 5.10 5.38 5.18
Support 4 (S4) 5.06